The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration

International Journal of Cancer

Volumn 140, Issue 4, 2017, Pages 888-899

  Perea, Francisco ^a   Bernal, Mónica ^a   Sánchez Palencia, Abel ^a   Carretero, Javier ^a   Torres, Cristina ^a   Bayarri, Clara ^a   Gómez Morales, Mercedes ^b   Garrido, Federico ^a,b,c   Ruiz Cabello, Francisco ^a,b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Inst Invest Biosanitaria Ibs GRANADA   (Spain)

Author keywords

HLA class I loss; immune escape; lung cancer; tumor infiltrating lymphocytes

Indexed keywords

ANTIGEN; BETA 2 MICROGLOBULIN; CD206 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; UNCLASSIFIED DRUG; GELATINASE; HLA ANTIGEN; MEMBRANE PROTEIN; SEPRASE; SERINE PROTEINASE; TUMOR PROTEIN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BETA2 M GENE; CANCER ASSOCIATED FIBROBLAST; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL INFILTRATION; CELL INTERACTION; CELL MEMBRANE DEPOLARIZATION; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; GENE LOCUS; GENETIC ANALYSIS; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE PERMISSIVE TUMOR MICROENVIRONMENT; IMMUNOCOMPETENT CELL; LMP2 GENE; LMP7 GENE; LUNG CARCINOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; NON IMMUNE PERMISSIVE TUMOR MICROENVIRONMENT; NON SMALL CELL LUNG CANCER; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; TISSUE STRUCTURE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; ANTIGEN PRESENTATION; BIOSYNTHESIS; CELL MOTION; DISEASE COURSE; FIBROBLAST; GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FIBROBLASTS; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HLA ANTIGENS; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84998881040     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30489     Document Type: Article

References (50)

1. Ladanyi A, Somlai B, Gilde K, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10:521–30.504.
2. Schumacher K, Haensch W, Roefzaad C, et al. Prognostic significance of activated CD8+ T cell infiltration within esophageal carcinomas. Cancer Res 2001; 61:3932–36.
3. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491–4.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960–4.
5. Bernal M, Concha A, Sáenz-López P, et al. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother 2011; 60:869–82.
6. Ryschich E, Notzel T, Hinz U, et al. Control of T cell mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005; 11:498–504.
7. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203–13.
8. Nakakubo Y, Miyamoto M, Cho Y, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736–42.
9. Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997; 3:817–9.
10. Carretero FJ, Del Campo AB, Flores-Martín JF, et al. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunol Immunother 2016; 65:47–59.
11. Johnson SK, Kerr KM, Chapman AD, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000; 27:27–35.
12. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232:199–209.
13. Salmon H, Franciszkiewicz K, Damotte D, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012; 122:899–910.
14. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348:74–80.
15. Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumour development. Immunol Today 1993; 14:491–9.
16. Marincola FM, Jafee EM, Hicklin DJ, et al. Escape of human solid tumors from. T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181–273.
17. Bodmer W, Browning MJ, Krausa P, et al. Tumour escape from immune response by variation in HLA expression and other mechanism. Ann N Y Acad Sci 1993; 690:42–49.
18. Koopman LA, Corver WE, Van Der Slik AR, et al. Multiple genetic alterations at chromosome 6p cause frequent and heterogeneous HLA class I antigen loss in cervical cancer. J Exp Med 2000; 191:961–76.
19. Seliger B, Stoehr R, Handke D, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2009; 59:529–40.
20. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20:728–40.
21. Garrido F, Cabrera T, Lopez-Nevot MA, et al. HLA class I antigens in human tumors. Adv Cancer Res 1995; 67:155–95.
22. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005; 65:6418–24.
23. Angell TE, Lechner MG, Jang JK, et al. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 2014; 20:6034–44.
24. Garrido F, Cabrera T, Aptsiauri N. “Hard” and “Soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249–56.
25. Travis WD, Colby TV, Corrin B, eds. Histological typing of lung and pleural tumours, 3rd ed. Heidelberg: Springer, 1999. 156p.
26. Sobin L, Gospodarowiaz M, Wittekind CH. TNM classification of malignant tumours UICC 2009, 7th edn. Chichester: Wiley, 2010. 310p.
27. Garrido F, Cabrera T, Accolla RS, et al. HLA and cancer: 12th International Histocompatibility Workshop study. In: Charron D, ed. Genetic diversity of HLA. Functional and medical implication. Proc. Twelfth International Histocompatibility Workshop and Conference, Vol. II. France: EDK, Sevres; 1997. 445–52.
28. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013; 339:1546–58.
29. del Campo AB, Kyte JA, Carretero J, et al. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 2014; 134:102–13.
30. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89–95.
31. Redondo M, Ruiz-Cabello F, Concha A, et al. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res 1991; 51:2463–8.
32. Redondo M, Concha A, Oldiviela R, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991; 51:4948–54.
33. Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; 98:1424–30.
34. Baba T, Shiota H, Kuroda K. Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients. Int J Clin Oncol 2013; 18:997–1004.
35. So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005; 65:5945–52.
36. Maleno I, Cabrera CM, Cabrera T, et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004; 56:244–53.
37. Bernal M, Ruiz-Cabello F, Concha A, et al. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother 2012; 61:1359–71.
38. Paschen A, Méndez RM, Jimenez P, et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103:759–67.
39. Carretero R, Cabrera T, Gil H, et al. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 2011; 129:839.
40. Valenzuela-Membrives M, Perea-García F, Sanchez-Palencia A, et al. Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer. Oncotarget, 2016; doi:10.18632/oncotarget.12264.
41. Mills CD, Lenz LL, Harris RA. A breakthrough: macrophage-directed cancer immunotherapy. Cancer Res 2016; 76:513–6.
42. Chen XH, Liu ZC, Zhang G, et al. TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol 2015; 65:34–42.
43. Mukhopadhyay S, Farver CF, Vaszar LT, et al. Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries. J Clin Pathol 2012; 65:51–57.
44. Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3.
45. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015; pii:. S0140-6736(15)01281–7.
46. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018–28.
47. Aptsiauri N, Carretero R, Garcia-Lora A, et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008; 57:1727–33.
48. Garrido F, Aptsiauri N, Doorduijn EM, et al. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 2016; 39:44–51.
49. Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 2008; 101:249–76.
50. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375:819–29.